Tag: Room

  • New Ebola case confirmed in the Democratic Republic of the Congo

    A new case of Ebola virus disease was confirmed today in the city of Beni in the Democratic Republic of the Congo (DRC).

    “While not welcome news, this is an event we anticipated. We kept response teams in Beni and other high risk areas for precisely this reason,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.  

    As part of the active Ebola surveillance system in place to respond to this ongoing outbreak in DRC, thousands of alerts are still being investigated every day. An alert is a person who has symptoms that could be due to Ebola, or any death in a high risk area that could have been as result of Ebola.

    As with all confirmed cases, efforts are already underway to find everyone who may have been in contact with the person in order to offer them the vaccine and monitor their health status.

    “WHO has worked side by side with health responders from the DRC for over 18 months and our teams are right now supporting the investigation into this latest case,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “Although the ongoing COVID-19 pandemic adds challenges, we will continue this joint effort until we can declare the end of this Ebola outbreak together.”

    The news of the confirmed case came minutes after the conclusion of a meeting of the International Health Regulations Emergency Committee on Ebola in DRC. The Emergency Committee will reconvene next week in order to re-evaluate their recommendations in light of this new information.

    Prior to this, the last person who was confirmed to have Ebola in DRC tested negative twice and was discharged from a treatment centre on 3 March 2020.

    As of 10 April 2020, 3456 confirmed and probable cases and 2276 deaths have occurred as a result of the outbreak.

    Read More
    https://www.who.int/news-room/detail/10-04-2020-new-ebola-case-confirmed-in-the-democratic-republic-of-the-congo

    Views: 0

  • MAEPS quarantine centre in Serdang to receive Covid-19 patients next week

    MAEPS quarantine centre in Serdang to receive Covid-19 patients next week

    MAEPS quarantine centre in Serdang to receive Covid-19 patients next week 1

    KUALA LUMPUR: The Covid-19 Low-Risk Patient Quarantine and Treatment Centre at the Malaysia Agro Exposition Park Serdang (MAEPS) in Serdang near here is expected to receive patients next week.

    Mardi Corp Group chief executive officer Zaidi Shahrim however said so far, it had no information on the exact date when the authorities would send the Covid-19 patients there for quarantine.

    “MAEPS will receive low-risk Covid-19 patients from around the Klang Valley, Malacca and several areas in Perak,” he said last night in an interview via Skype that broadcast live on the Bernama 7.45 programme.

    On the challenges faced throughout the process of transforming MAEPS into a quarantine centre in just a short period of time, Zaidi said said it was difficult to get supplies from contractors as many were ‘bound’ by the Movement Control Order (MCO).

    “We received the instruction during the first phase of the MCO but Alhamdulillah, with the close cooperation between various government agencies such as the Ministry of Health (MOH), Nadma (the National Disaster Management Agency), the Fire and Rescue Department and private companies, we managed to realise it within four days,” he added.

    Zaidi said MAEPS is equipped with hospital-like facilities such as beds, bathrooms, dressing room, toilet, lounge and so on.

    Among the services provided at the centre are clinical services, ward for Covid-19 patients, resuscitation rooms to stabilise patients in emergency situations, ambulance, pharmacy, X-ray, and pathology laboratory services.

    The quarantine centre which has the capacity to place up to 600 patients at any one time is coordinated by Nadma with the cooperation of the MOH, the Malaysian Armed Forces, the Fire and Rescue Department, the Civil Defence Force, the Social Welfare Department and the Public Works Department. — Bernama

    MAEPS quarantine centre in Serdang to receive Covid-19 patients next week
    Read More
    https://www.thesundaily.my/local/maeps-quarantine-centre-in-serdang-to-receive-covid-19-patients-next-week-MB2245538

    Views: 0

  • Speed of Covid-19 deaths shock doctors and nurses

    Speed of Covid-19 deaths shock doctors and nurses

    Speed of Covid-19 deaths shock doctors and nurses 2

    NEW YORK: One medical worker called it “insane”, another said it induces paranoia – the speed with which patients are dying from the novel coronavirus is shocking even veteran doctors and nurses as they scramble to determine how to stop such sudden deterioration.

    Patients “look fine, feel fine, then you turn around and they’re unresponsive”, said Diana Torres, a nurse at Mount Sinai Hospital in New York, the epicentre of the pandemic in the US where the virus has infected nearly 430,000 people and caused more than 14,700 deaths.

    “I’m paranoid, scared to walk out of their rooms.”

    It isn’t just the elderly or patients with underlying health conditions, who can be fine one minute, and at death’s door the next.

    It can happen for the young and healthy, too, health professionals told Reuters.

    A young woman died unexpectedly while nurse Laurie Douglas was on duty at Our Lady of the Lake Hospital in Baton Rouge, Louisiana.

    After 34 years on the job, Douglas said she normally has “an intuition of who is going to fade and who may improve”.

    “But these people are throwing that out the window.

    “Last week, she was planning her wedding.

    “This week, her family is planning her funeral,“ she said, referring to the deceased patient.

    Patients might enter the hospital with strong oxygen levels and be engaged in happy conversation, said a resident emergency doctor at New York-Presbyterian Hospital, only to be “gasping for breath” and intubated a few hours later.

    “The scary thing is there are no rules to it,“ the resident said on condition of anonymity.

    These scenes are playing out everywhere as Covid-19 has infected more than 1.4 million worldwide and killed more than 85,000 as of Wednesday.

    The quick turns for the worse are likely products of an “overly exuberant” reaction by the immune system as it fights the virus, said Dr Otto Yang, an infectious disease specialist at the UCLA Medical Centre in Los Angeles.

    Called a cytokine storm, it occurs when the body overproduces immune cells and their activating compounds – cytokines – causing dangerously high blood pressure, lung damage and organ failure.

    Emily Muzyka, 25, a nurse in the New York suburbs, said she reached her breaking point last week, when a relatively healthy 44-year-old woman needed sudden intubation.

    “I had a meltdown that night,“ she said.

    “I cried to my boyfriend.”

    Intubation refers to inserting a tube into the mouth and through the airway of a Covid-19 patient struggling to breathe, so they can be hooked to a mechanical ventilator.

    Journalist Anick Jesdanun, who was in good health and had run 83 marathons, died last week from Covid-19, according to a post on Facebook by his cousin Prinda Mulpramook.

    Jesdanun, who was 51, at first didn’t need hospitalisation, according to the post.

    He had begun to recover and showed clear lungs and strong vital signs during a doctor’s visit in late March. But “a sudden setback” sent him to the emergency room on April 1, and “13 hours later we lost him”, Mulpramook wrote.

    A nurse at Mount Sinai’s intensive care unit recalled watching patients’ kidneys quickly shut down, adding that many require intravenous drips of the blood thinner Heparin.

    “It’s insane how sick they get, how quickly.

    “We’re really trying hard to figure out how to treat them.”

    Some of those hospitals are experimenting with unproven drugs in hopes of helping patients, including the anti-malaria medication hydroxychloroquine.

    “We’re essentially throwing the kitchen sink at these patients,“ a doctor said.

    Speed of Covid-19 deaths shock doctors and nurses
    Read More
    https://www.thesundaily.my/home/speed-of-covid-19-deaths-shock-doctors-and-nurses-AF2241516

    Views: 0

  • Medical Product Alert N°4/2020

    Medical Product Alert N°4/2020

    This Medical Product Alert relates to a number of confirmed falsified chloroquine products circulating in the WHO region of Africa. Please note that this Medical Product Alert n°4/2020 will be updated as new reports of falsified chloroquine are received and validated by WHO.

    Between 31 March and 2 April 2020, the WHO global surveillance and monitoring system on substandard and falsified (SF) medical products received nine reports of confirmed falsified chloroquine products from three countries. All reported products were identified at patient level and all have been confirmed as falsified.

    This WHO medical product alert N°4/2020 refers to nine different falsified chloroquine products, with different presentations (see Table 1). It is important to note that widespread vigilance is required from all countries, regardless of where the product was originally identified.

    Table 1: List of identified falsified chloroquine products, subject of WHO Alert N°4/2020
    table1

    All the products listed in Table 1 are confirmed as falsified, on the basis that they deliberately/fraudulently misrepresent their identity, composition or source. Indeed, it can be noted that:

    • either: the products do not contain the correct amount of the active pharmaceutical ingredient, based on the results of preliminary or full compendial analysis;
    • and/or: the products were not produced by the manufacturer whose name is stated on the product labels, and the variable data (batch number and dates) of the above products do not correspond to genuine manufacturing records;
    • and/or: the manufacturer whose name is stated on the product labels does not exist.

    Chloroquine phosphate or sulfate is referenced on the WHO Model List of Essential Medicines for the treatment of Plasmodium vivax infection (malaria). Large clinical trials are under way to generate the robust data needed to establish the efficacy and safety of chloroquine and hydroxychloroquine in the treatment of COVID-19. These medicines are currently authorized for malaria and certain autoimmune diseases and it is important that patients do not face shortages caused by stockpiling or use outside the authorized indications. 
    Both chloroquine and  hydroxychloroquine can have serious side effects, especially at high doses or when combined with other medicines.

    The SOLIDARITY trial, led by WHO, is reviewing potential treatments for COVID-19. Please refer to  WHO medical product alert n°3/2020 for general information on falsified medical products in relation to the management 
    of COVID-19.

    For photographs of products listed in Table 1, please refer to the WHO Medical Product Alert website, and 
    to the annex of this medical product alert n°4/2020 (see pages 3-7).

    WHO requests increased vigilance within the supply chains of countries likely to be affected by these falsified products. Increased vigilance should include hospitals, clinics, health centres, wholesalers, distributors, pharmacies and any other suppliers of medical products.

    If you are in possession of the above products, please do not use. If you have used these falsified products, or if you suffer an adverse reaction/event having used these products, you are advised to seek immediate medical advice from a qualified healthcare professional, and to report the incident to the National Regulatory Authorities/National Pharmacovigilance Centre.

    All medical products must be obtained from licensed, authentic and reliable sources. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of doubt.

    National regulatory/health authorities are advised to immediately notify WHO if these falsified products are discovered in their country. If you have any information concerning the manufacture, distribution, or supply of these products, please contact: rapidalert@who.int. 

    WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products
    For more information, please visit: www.who.int/medicines/regulation/ssffc/en/ 

    Annex: Photographs of falsified chloroquine products circulating in the WHO region of Africa, Medical Product Alert N°4/2020

    CAMEROON

    Photographs of confirmed falsified Chloroquine Phosphate (100mg)
    ChloroquinePhosphate250mgCameroon-1

    Photographs of confirmed falsified Chloroquine Phosphate (250mg)
    ChloroquinePhosphate250mgCameroon-2

    Photographs of confirmed falsified Chloroquine Phosphate 250mg
    ChloroquinePhosphate250mg-Cameroon 3

    DEMOCRATIC REPUBLIC OF CONGO

    Photographs of confirmed falsified CLOROQUINE 250MG
    ChloroquinePhosphate250mgDRC1

    Photographs of confirmed falsified Chloroquine Phosphate 250mg
    ChloroquinePhosphate250mgDRC2

    NIGER

    Photographs of confirmed falsified Samquine 100 (100mg)

    Samquine100-100mgNiger 1

    Photographs of confirmed falsified Chloroquine phosphate tablets B.P 100mg

    Chloroquine-phosphate-tabletsB.P100mgNiger2

    Photographs of confirmed falsified Niruquine (100mg)
    Niruquine00mgNiger3

     

    Medical Product Alert N°4/2020
    Read More
    https://www.who.int/news-room/detail/09-04-2020-medical-product-alert-n4-2020

    Views: 0

  • WHO public consultation on draft Target Product Profiles for Tuberculosis Preventive Treatment

    Tuberculosis (TB) is a major yet preventable global health problem, with an estimated 10 million new cases worldwide in 2018, resulting in more than 1.5 million deaths, making it the leading infectious disease cause of death worldwide. An estimated one fourth of the world’s population is infected with the TB bacterium, of whom 5–10% advance to active TB disease in their lifetime.

    Prevention of TB is a crucial component of the World Health Organization (WHO) End TB Strategy that calls for 90% coverage of TB preventive treatment (TPT) among persons living with HIV (PLHIV) and household contacts of infectious TB cases by 2035. The UN high-level meeting on TB, in September 2018, further emphasized the need to strengthen implementation of TPT and called for 30 million people, including 4 million children under 5 years of age to receive TPT by 2022.

    However, uptake and scale-up of TPT have been slow, mainly due to the limitations of both diagnostic assays and available regimens (long duration, cost, toxicity, adherence issues, and operational aspects), indicating the need for new short, safe, efficacious and easy-to-take regimens for the treatment of TB infection and prevention of TB disease. The WHO has developed draft Target Product Profiles (TPPs) for TPT to align developers’ performance and operational targets for new TPT regimens with the needs of end-users.

    The draft TPPs are now available online for comment.

    WHO invites comments or feedback from all stakeholders by 27 April 2020 via this link:

    Based on the comments received on this draft, WHO will prepare the final non-draft TPP (version 1.0), which will be posted on WHO’s website and uploaded into the (WHO) Product Profile Directory by October 2020.

    Read More
    https://www.who.int/news-room/detail/31-03-2020-who-public-consultation-on-draft-target-product-profiles-for-tuberculosis-preventive-treatment

    Views: 0

  • A meeting on digital innovations, TB and implementation research organised by WHO and the European Respiratory Society

    A meeting on digital innovations, TB and implementation research organised by WHO and the European Respiratory Society

    Group of people posing after a meeting on TB, in Geneva

    WHO’s Global Tuberculosis Programme (WHO/GTB) and the European Respiratory Society convened a technical meeting on digital innovations, TB and implementation research, in Geneva on 7 February 2020. This meeting brought together funders,
    partners, representatives of national TB programmes, civil society and scientists to discuss the challenges and opportunities when evaluating, integrating and scaling up digital technologies under programmatic settings.  Specifically, this meeting
    sought to receive input on the elements of a toolkit on implementation research that is currently being developed by WHO/GTB and the Special Programme for Research and Training in Tropical Diseases (TDR) to support evidence-informed use of
    digital technologies under programmatic settings. Th etoolkit will be launched in mid-2020. Considering that several countries are updating their national TB strategic plans and preparing funding proposals for submission to the Global Fund, this meeting
    also sought to create mutual understanding on the importance of resourcing implementation science to bridge the divide between research and practice.

    This present meeting, is the latest in a series of efforts by WHO/GTB to facilitate the meaningful use of digital technologies for TB prevention and care. It
    was preceded by a one-day workshop on 6 February held at the same venue for partner agencies of the ASCENT project. ASCENT is a UNITAID-funded project that started in 2019 with the aim of increasing demand and adoption of affordable digital technologies for TB medication adherence. The project is led by KNCV in partnership with Aurum Institute for Health
    Research, PATH and the London School of Hygiene and Tropical Medicine. Activities are running in Ethiopia, the Philippines, South Africa, Ukraine and Tanzania UR. This was the first in a series of annual meetings that will be coordinated by the WHO/GTB
    to assess progress in implementation of country activities and results from the interventions.

    A meeting on digital innovations, TB and implementation research organised by WHO and the European Respiratory Society
    Read More
    https://www.who.int/news-room/detail/26-04-2020-a-meeting-on-digital-innovations-tb-and-implementation-research-organised-by-who-and-the-european-respiratory-society

    Views: 0

  • Strengthening accountability to end TB

    WHO today released a Checklist to enable Member States and their partners to assess the status of work at the national level to strengthen accountability to End TB, principally: national commitments made, actions taken on those commitments, monitoring & reporting approaches, and the nature of any high-level review mechanisms. The Checklist has been developed in response to requests from Member States, regions, civil society and partners as a tool to support the adaptation and implementation of the WHO Multisectoral Accountability Framework (MAF-TB) released in 2019. It responds also to the UN General Assembly request to WHO to ensure implementation of the Framework.

    There are four components of the MAF-TB that form a cycle for strengthening accountability: Commitments, Actions, Monitoring and Reporting, and Review, that were released during the World Health Assembly in May, 2019. In the political declaration of the first UN high-level meeting on TB, world leaders called for WHO to finalize the framework and ensure its implementation in 2019.

    After its publication in May, 2019, WHO began work with pathfinding country counterparts who were seeking to move ahead on key elements including, among others: formal adoption of country-specific targets for 2022 for increased TB case detection and treatment in line with the global targets in the political declaration; updating or development of new national TB strategic plans based on 2022 and 2030 targets and other new commitments; coordination platforms across sectors and stakeholders; formalizing engagement with civil society across End TB efforts;  producing robust performance reports; and, using those reports to inform high-level review bodies that will assess and drive faster progress.  Based on the MAF-TB document, relevant country experiences, and specific requests from countries and partners, WHO developed the MAF-TB Checklist. The Checklist is especially relevant for high TB burden countries, but has content relevant to all countries.  The appropriateness of different approaches may vary, according to national constitutional, legal and/or regulatory frameworks or other relevant factors.

    The MAF-TB Checklist has three annexes on:

    1. engagement across government ministries and bodies;
    2. engagement of civil society and affected communities; and,
    3. adoption  and implementation of WHO TB guidance.

    In releasing this MAF-TB Checklist today, Dr Tereza Kasaeva, Director of the WHO Global TB Programme noted,  “At this enormously difficult time, all countries and partners are focused on the COVID-19 pandemic.  Lessons learnt from ongoing TB programmes are helping the response. Likewise, TB efforts will benefit from learning underway on collaboration, innovation and accountability in confronting the virus.”

    WHO will be helping Ministries of Health and partners to use the Checklist, hold related consultations and move forward with more effective collaboration and review mechanisms.  The WHO Civil Society Task Force on TB also will support countries and civil society partners, using the Checklist. Progress in strengthening accountability will be assessed in the 2020 Report of the UN Secretary-General on progress since the 2018 TB UN high-level meeting, as well as in the WHO Global TB Report 2020.

    The WHO TB Civil Society Task Force, National TB  Programme Managers and other country officials, WHO staff at all levels, consultants working with WHO and The Global Fund, and staff of partner agencies, contributed content to, and/or provided feedback on, the MAF-TB Checklist during its development.   Access the Checklist and 3 annexes.  

    An online form of the checklist will be available shortly here, along with additional information.  

    Translations of the Checklist and annexes, as soon as available in Arabic, Chinese, French, Russian and Spanish, will be posted at the above link as well.   Kindly contact gtbprogramme@who.int if you have questions regarding the MAF-TB Checklist or to request versions in MS Word format if needed.

     

    Read More
    https://www.who.int/news-room/detail/08-04-2020-strengthening-accountability-to-end-tb

    Views: 0

  • Children’s story book released to help children and young people cope with COVID-19

    Children’s story book released to help children and young people cope with COVID-19

    GENEVA, 9 April 2020 – A new story book that aims to help children understand and come to terms with COVID-19 has been produced by a collaboration of more than 50 organizations working in the humanitarian sector, including the World Health Organization, the United Nations Children’s Fund, the United Nations High Commissioner for Refugees, the International Federation of Red Cross and Red Crescent Societies and Save the Children.

    With the help of a fantasy creature, Ario, “My Hero is You, How kids can fight COVID-19!” explains how children can protect themselves, their families and friends from coronavirus and how to manage difficult emotions when confronted with a new and rapidly changing reality.

    The book – aimed primarily at children aged 6-11 years old – is a project of the Inter-Agency Standing Committee Reference Group on Mental Health and Psychosocial Support in Emergency Settings, a unique collaboration of United Nations agencies, national and international nongovernmental organizations and international agencies providing mental health and psychosocial support in emergency settings.

    During the early stages of the project, more than 1700 children, parents, caregivers and teachers from around the world shared how they were coping with the COVID-19 pandemic. The input was invaluable to script writer and illustrator Helen Patuck and the project team in making sure that the story and its messages resonated with children from different backgrounds and continents.

    In order to reach as many children as possible, the book will be widely translated, with six language versions released today and more than 30 others in the pipeline. It is being released as both an online product and audio book.

    ————

    Download the book here

    My Hero is You: all language versions

    Quotes from collaborating partners

     World Health Organization

    Dr Tedros Adhanom Ghebreyesus, Director-General (awaiting clearance)

    “Previous humanitarian emergencies have shown us how vital it is to address the fears and anxiety of young people when life as they know it gets turned upside down. We hope that this beautifully-illustrated book, which takes children on a journey across time zones and continents, will help them to understand what they can do to stay positive and keep safe during the coronavirus outbreak.”

    UNICEF

    Henrietta Fore, Executive Director

    “All over the world, children’s lives have been completely upended — the majority of them living in countries with some form of restricted movement or lockdown. This wonderful book helps children understand and navigate this new landscape and learn how they can take small actions to become the heroes in their own stories.”

    UNHCR

    Filippo Grandi, United Nations High Commissioner for Refugees.

    “This is an important resource for children around the world with a strong message of inclusion at its heart – that this pandemic can only be beaten if everyone is included in its prevention and response. Children, including those who are refugees, displaced and stateless, can help too. No-one is protected unless we are all protected”.

    UNESCO

    Audrey Azoulay, Director General

    “Sharing facts and reliable information is vital to respond to COVID-19, and I wish to commend the creativity and passion of all artists, writers and publishers who find compelling ways to translate and craft stories and artwork so they can reach children and families to comfort and guide them through a distressing situation.  UNESCO is proud to support this initiative and we see this as an example of the contribution of the artistic community to the well-being and resilience of all.”

    —–

    For requests relating to translations

    Inter-Agency Standing Committee Reference Group on Mental Health and Psychosocial Support in Emergency Settings, Email: mhpss.refgroup@gmail.com

     

     

     

     

    Children’s story book released to help children and young people cope with COVID-19
    Read More
    https://www.who.int/news-room/detail/09-04-2020-children-s-story-book-released-to-help-children-and-young-people-cope-with-covid-19

    Views: 0

  • WHO Timeline – COVID-19

    31 Dec 2019

    China reported a cluster of cases of pneumonia in Wuhan, Hubei Province. A novel coronavirus was eventually identified.

    1 January 2020

    WHO had set up the IMST (Incident Management Support Team) across the three levels of the organization: headquarters, regional headquarters and country level, putting the organization on an emergency footing for dealing with the outbreak.

    4  January 2020

    WHO reported on social media that there was a cluster of pneumonia cases – with no deaths – in Wuhan, Hubei province. 

    5 January 2020

    WHO published our first Disease Outbreak News on the new virus. This is a flagship technical publication to the scientific and public health community as well as global media. It contained a risk assessment and advice, and reported on what China had told the organization about the status of patients and the public health response on the cluster of pneumonia cases in Wuhan.

    10 January 2020

    WHO issued a comprehensive package of technical guidance online with advice to all countries on how to detect, test and manage potential cases, based on what was known about the virus at the time.

    Evidence at that time suggested there was “no or limited human-to-human transmission.” Based on experience with SARS and MERS and known modes of transmission of respiratory viruses, infection and prevention control guidance were published to protect health workers recommending droplet and contact precautions when caring for patients, and airborne precautions for aerosol generating procedures conducted by health workers.

    12 January 2020

    China shared the genetic sequence of COVID-19. 

    13 January 2020

    Officials confirm case of COVID-19 in Thailand, the first recorded case outside of China.  

    14 January 2020

    Dr. Maria Van Kerkhove noted in a press briefing there had been limited human-to-human transmission of the coronavirus (in the 41 confirmed cases), mainly through family members, and that there was a risk of a possible wider outbreak. Dr. Kerkhove noted that human-to-human transmission would not be surprising given our experience with SARS, MERS and other respiratory pathogens. 

    20-21 January 2020

    WHO experts from its China and Western Pacific regional offices conducted a brief field visit to Wuhan.

    22 January 2020

    WHO mission to China issued a statement saying that there was evidence of human-to-human transmission in Wuhan but more investigation was needed to understand the full extent of transmission.

    22- 23 January 2020

    The WHO Director- General convened an Emergency Committee (EC) under the International Health Regulations (IHR 2005) to assess whether the outbreak constituted a public health emergency of international concern. The independent members from around the world could not reach a consensus based on the evidence available at the time. They asked to be reconvened within 10 days after receiving more information.

    28 January 2020

    A senior WHO delegation led by the Director-General travelled to Beijing to meet China’s leadership, learn more about China’s response, and to offer any technical assistance. 

    While in Beijing, Dr. Tedros agreed with Chinese government leaders that an international team of leading scientists would travel to China on a mission to better understand the context, the overall response, and exchange information and experience.

    11-12 February 2020

    WHO convened a Research and Innovation Forum on COVID-19, attended by more than 400 experts and funders from around the world, which included presentations by George Gao, Director General of China CDC, and Zunyou Wu, China CDC’s chief epidemiologist. 

    16-24 February 2020

    The WHO-China Joint mission, which included experts from Canada, Germany, Japan, Nigeria, Republic of Korea, Russia, Singapore and the US (CDC, NIH) spent time in Beijing and also travelled to Wuhan and two other cities. They spoke with health officials, scientists and health workers in health facilities (maintaining physical distancing). The report of the joint mission can be found here: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf

     

    Read More
    https://www.who.int/news-room/detail/08-04-2020-who-timeline—covid-19

    Views: 0